An investigation of clinical studies suggests those with multiple objectives should have at least 90% power for each endpoint

Journal of Clinical Epidemiology

Volumn 59, Issue 1, 2006, Pages 1-6

  Borm, George F ^a   Houben, Rein M G J ^a   Welsing, Paco M J ^a   Zielhuis, Gerhard A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trial; Intention to treat; Per protocol; Power; Sample size

Indexed keywords

ANALYTIC METHOD; ANALYTICAL PARAMETERS; CALCULATION; CLINICAL STUDY; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL PROTOCOLS; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; GOALS; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 29144523248     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2005.03.020     Document Type: Review

References (15)

1. The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Points to consider on multiplicity issues in clinical trials. London: 2002.
2. P. Armitage Attitudes in clinical trials Stat Med 17 1998 2675 2683
3. The European Agency for the Evaluation of Medicinal Products. Statistical principles for clinical trials. Note for guidance on statistical principles for clinical trials. London: 1998.
4. J.M. Lachin Statistical considerations in the intent-to-treat principle Control Clin Trials 21 2000 167 189
5. A.D. McMahon Study control, violators, inclusion criteria and defining explanatory and pragmatic trials Stat Med 21 2002 1365 1376
6. C.C. Wright, and J. Sim Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis J Clin Epidemiol 56 2003 833 842
7. The European Agency for the Evaluation of Medical Products. Committee for proprietary medicinal products. Points to consider on missing data. London: 2001.
8. J. Shao, and B. Zhong Last observation carry-forward and last observation analysis Stat Med 22 2003 2429 2441
9. J.M. Engels, and P. Diehr Imputation of missing longitudinal data: a comparison of methods J Clin Epidemiol 56 2003 968 976
10. M.A. Proschan, and M.A. Waclawiw Practical guidelines for multiplicity adjustment in clinical trials Control Clin Trials 21 2000 527 539
11. A.J. Sankoh, R.B. D'Agostino, and M.F. Huque Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues Stat Med 22 2003 3133 3150
12. Van Riel PLCM, Van Gestel AM, Scott DG. EULAR handbook of clinical assessments in rheumatoid arthritis. Alphen aan de Rijn, the Netherlands: Van Zuiden Communications.
13. D. Van der Heijde How to read radiographs according to the Sharp/Van der Heijde Method J Rheumatol 26 1999 743 745
14. J.J. Anderson, and M.C. Chernoff Sensitivity to change of rheumatoid arthritis clinical trial outcome measures J Rheumatol 20 1993 535 537
15. S.T. Brookes, E. Whitely, M. Egger, G.D. Smith, P.A. Mulheran, and T.J. Peters Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test J Clin Epidemiol 57 2004 229 236